dl1520 (ONYX-015)

ONYX-015 (CI-1042) is an adenovirus modified selectively to replicate in and kill cells that harbor p53 mutations for the potential treatment of various solid tumors, including head and neck, gastrointestinal and pancreatic tumors

Also Known As:

Networked: 142 relevant articles (16 outcomes, 49 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kirn, D: 12 articles (02/2007 - 03/2000)
2.	Nemunaitis, J: 6 articles (11/2007 - 08/2000)
3.	Randlev, B: 6 articles (03/2005 - 08/2000)
4.	Heise, C: 6 articles (01/2002 - 03/2000)
5.	Ganly, I: 6 articles (03/2001 - 03/2000)
6.	Qian, Cheng: 5 articles (12/2007 - 04/2004)
7.	Kirn, David H: 5 articles (11/2007 - 02/2002)
8.	Reid, Tony R: 4 articles (08/2015 - 02/2003)
9.	Korn, W M: 4 articles (11/2009 - 10/2000)
10.	Portella, Giuseppe: 4 articles (10/2008 - 06/2002)

Related Diseases

1.	Neoplasms (Cancer) 11/01/2000 - "Intraperitoneal treatment with dl1520 led to complete tumor eradication and/or significantly improved survival in two p53(-) nude mouse-human ovarian tumor xenograft models. " 03/01/2000 - "Using a pair of isogenic cell lines that differ only in their p53 status, we demonstrate here that although ONYX-015 can replicate in both p53 wild-type and mutant cells in vitro, the virus demonstrates significantly greater antitumor activity against mutant p53 tumors in vivo. " 02/01/2011 - "Oncolytic adenoviruses, such as ONYX-015, have been tested in clinical trials for currently untreatable tumors, but have yet to demonstrate adequate therapeutic efficacy. " 01/01/2022 - "Oncorine and ONYX-015 are oncolytic adenoviral vectors that have been shown to be effective against some types of cancer. " 05/15/2000 - "The use of an Elb55k-deficient adenovirus, ONYX-015, to selectively target tumor cells containing a mutated p53 gene has produced promising results. "
2.	Carcinoma (Carcinomatosis) 11/01/2006 - "ONYX-015 combined with MMC can produce significant cytotoxicity against T-24 cells and enhance therapeutic efficacy against bladder carcinoma." 11/01/2002 - "We performed a Phase II trial of an oncolytic replication-selective adenovirus (dl1520, also known as Onyx-015) administered by hepatic artery infusion in patients with gastrointestinal carcinoma metastatic to the liver (n = 27). " 02/09/2012 - "The recombinant virus AD55-Apoptin has more significant antitumor effect for hepatocelluar carcinoma cell lines (in vitro) than that of AD55 and even ONYX-015 but no or little impair on normal cell lines. " 10/15/2008 - "The antitumor efficacies of the E1ADeltaCR2 (dl922-947) and DeltaE1B55K (dl1520) mutants were compared in human thyroid anaplastic carcinoma cells in culture and in xenografts in vivo. " 01/01/2003 - "In the course of a clinical trial, a patient with paired abdominal wall implants from a primary gall bladder carcinoma was injected with ONYX-015, 1 x 10(10) viral particles/lesion, followed by sequential excision of the lesions at 37 h and 7 days. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 02/01/2003 - "Therefore, we undertook a trial of the feasibility, tolerability, and efficacy of EUS injection of ONYX-015 into unresectable pancreatic carcinomas. " 02/01/2001 - "We carried out a phase I dose escalation study of ONYX-015 in patients with unresectable pancreatic cancer. " 10/01/2011 - "Cell killing efficacy was higher for dl922-947 than for adenovirus type 5 (Ad5) and the clinically approved dl1520 in pancreatic cancer cells with K-ras, p16 and p53 mutations. " 09/01/2010 - "ONYX-015 is an oncolytic attenuated adenovirus that exhibits replication preferentially in malignant cells, causing cell death, and this has also been injected into pancreatic cancers under EUS guidance. " 09/01/2005 - "Recently, a clinical trial (phase I and II) using an oncolytic adenovirus, ONYX-015, was completed in patients with pancreatic cancer. "
4.	Squamous Cell Carcinoma of Head and Neck 09/01/2011 - "Finally, the efficacy of VVhEA was compared with dl1520 in vivo in a human HNSCC model. " 03/01/2002 - "However, the most significant clinical advances for the use of gene therapy in advanced HNSCC involves two agents: Adp53 and ONYX-015. " 09/01/2000 - "The E1-b attenuated adenovirus, ONYX-015 (Onyx Pharmaceuticals, Richmond, CA), has demonstrated antitumoral activity in patients with recurrent squamous cell carcinoma of the head and neck. " 09/01/2011 - "Oncolytic viral therapy represents a promising strategy for the treatment of head and neck squamous cell carcinoma (HNSCC), with dl1520 (ONYX-015) the most widely used oncolytic adenovirus in clinical trials. " 09/01/2000 - "A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)."
5.	Anaplastic Thyroid Carcinoma 10/15/2008 - "We showed that the efficacy of dl922-947 exceeded that of dl1520 in all tested anaplastic thyroid carcinoma cells in vitro and in vivo. " 10/15/2008 - "Our data showed that dl922-947 had a higher oncolytic activity compared with dl1520 in anaplastic thyroid carcinoma cell lines and might represent a better option for virotherapy of anaplastic thyroid carcinoma. " 10/01/2003 - "ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells." 06/01/2002 - "ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines." 10/01/2003 - "Our results suggest that the combination of ONYX-015 and radiotherapy should be considered for experimental trials in patients with anaplastic thyroid carcinoma."

Related Drugs and Biologics

1.	Mitoxantrone (Novantrone)
2.	Hormones (Hormone)
3.	Icodextrin (Extraneal)
4.	Docetaxel (Taxotere)
5.	dl1520 (ONYX-015)
6.	Cisplatin (Platino)
7.	Therapeutic Uses
8.	Fluorouracil (Carac)
9.	Antineoplastic Agents (Antineoplastics)
10.	Tumor Suppressor Protein p14ARF (p14ARF)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Intravenous Administration
3.	Therapeutics
4.	Radiotherapy
5.	Intravenous Infusions